


PHARMACEUTICAL 2022


MusclePharm Corp Rank 373 of 475







PHARMACEUTICAL 2022





The relative strengths and weaknesses of MusclePharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MusclePharm Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 568% points. The greatest weakness of MusclePharm Corp is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 619% points.

The company's Economic Capital Ratio, given in the ranking table, is -321%, being 45% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	10,967
Cost of Goods Sold	44,671
Intangible Assets	35
Liabilities, Current	41,075
Liabilities, Non-Current	0
Other Assets	203
Other Compr. Net Income	0
Other Expenses	9,845
Other Liabilities	2,326
Other Net Income	1,499
Property and Equipment	5.0
Research and Development	0
Revenues	50,042
Selling, General and Administrative Expense	9,891

Output Variable	Value in 1000 USD
Assets	11,210
Liabilities	43,401
Expenses	64,407
Stockholders Equity	-32,191
Net Income	-12,866
Comprehensive Net Income	-12,866
Economic Capital Ratio	-321%